Jonathan Sive

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Outcomes in older adults with acute lymphoblastic leukaemia (<scp>ALL</scp>): results from the international <scp>MRC UKALL XII</scp>/<scp>ECOG</scp>2993 trial

Jonathan Sive, Georgina Buck, Adele K. Fielding et al. · British Journal of Haematology · 2012 · 198 citations · Full text

Medicine, Geriatric Medicine, Oncology +13

Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

Jonathan Sive, Kirsty Cuthill, Hannah Hunter et al. · British Journal of Haematology · 2021 · 56 citations

Medicine, Hematology, Internal Medicine +17

Adenoviremia Has Limited Clinical Impact in the Majority of Patients Following Alemtuzumab-Based Allogeneic Stem Cell Transplantation in Adults

Jonathan Sive, Kirsty Thomson, Emma Morris et al. · Clinical Infectious Diseases · 2012 · 31 citations

Medicine, Hematology, Immunology +16

High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry

Zara Sayar, Anna Weatherill, Stephen Keddie et al. · Blood Advances · 2020 · 24 citations · Full text

Medicine, Hematology, Internal Medicine +11